Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults with post- and precapillary pulmonary hypertension due to heart failure. The Rahway, N.J., ...
The phase 2 Cadence trial met its primary endpoint, showing that Winrevair improved the ability of blood to transition through the lungs to the heart in patients with combined post- and precapillary ...
What does Rick Pazdur's new role mean for the FDA? And how much credit can the president take for lowering GLP-1 drug prices?
Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback